MONTI, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.832
EU - Europa 4.774
AS - Asia 1.189
OC - Oceania 89
AF - Africa 59
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 3
Totale 14.955
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.808
RU - Federazione Russa 1.842
PL - Polonia 680
IE - Irlanda 608
SE - Svezia 529
SG - Singapore 370
IT - Italia 363
HK - Hong Kong 319
CN - Cina 227
UA - Ucraina 218
DE - Germania 184
FI - Finlandia 153
GB - Regno Unito 89
TR - Turchia 89
AU - Australia 88
IN - India 86
CI - Costa d'Avorio 47
BE - Belgio 31
JO - Giordania 30
VN - Vietnam 27
CA - Canada 22
ID - Indonesia 20
CH - Svizzera 18
FR - Francia 18
NL - Olanda 11
BR - Brasile 8
KR - Corea 8
CZ - Repubblica Ceca 7
LT - Lituania 6
SC - Seychelles 6
RO - Romania 5
EG - Egitto 4
ES - Italia 3
EU - Europa 3
SK - Slovacchia (Repubblica Slovacca) 3
AM - Armenia 2
JP - Giappone 2
KZ - Kazakistan 2
PK - Pakistan 2
AT - Austria 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BF - Burkina Faso 1
BY - Bielorussia 1
EC - Ecuador 1
GR - Grecia 1
IQ - Iraq 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
MD - Moldavia 1
MX - Messico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PT - Portogallo 1
Totale 14.955
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.602
Fairfield 870
Warsaw 676
Dublin 607
Chandler 588
Ashburn 431
Woodbridge 404
Seattle 349
Cambridge 345
Wilmington 336
Jacksonville 295
Houston 289
Singapore 267
Ann Arbor 207
Hong Kong 187
Princeton 157
Altamura 136
Lawrence 130
Buffalo 126
Beijing 113
Boardman 97
Boston 95
Melbourne 87
Medford 83
Mumbai 78
Izmir 75
Florence 63
Bremen 48
Abidjan 47
Shanghai 44
Norwalk 41
San Diego 38
Falls Church 33
Brussels 31
New York 20
Dearborn 19
Jakarta 19
Moscow 19
Bern 18
Dong Ket 18
Los Angeles 16
Andover 15
Toronto 15
Washington 15
Hillsboro 14
Milan 14
Munich 14
Helsinki 12
West Jordan 12
Padova 9
Redmond 8
Salerno 8
Verona 8
Auburn Hills 7
Brno 7
Frankfurt Am Main 7
Kent 7
London 7
Old Bridge 7
Saint Petersburg 7
Bagno a Ripoli 5
Phoenix 5
Seoul 5
Tappahannock 5
Yubileyny 5
Aachen 4
Avigliano 4
Cluj-Napoca 4
Frankfurt am Main 4
Laurel 4
Nanjing 4
Ottawa 4
Ferriere 3
Modena 3
Redwood City 3
Rome 3
San Mateo 3
Stockholm 3
Almaty 2
Barcelona 2
Bastia umbra 2
Bratislava 2
Chiswick 2
Faisalabad 2
Falkenstein 2
Grevenbroich 2
Jiaxing 2
Kilburn 2
Kunming 2
Meppel 2
Newark 2
Osimo 2
Pune 2
Radomsko 2
Rufina 2
Yerevan 2
Alcalá De Guadaira 1
Amman 1
Amsterdam 1
Anápolis 1
Totale 10.408
Salva come PNG Salva come JPEG
Nome #
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 269
Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study 253
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 233
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 223
Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases 203
The metabolic fingerprints of HCV and HBV infections studied by Nuclear Magnetic Resonance Spectroscopy 170
Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review 165
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 165
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 165
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis 163
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 161
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 156
Host genetic determinants in HCV-related mixed cryoglobulinemia 155
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 153
A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection 151
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C 151
Association Between Persistent Lymphatic Infection By Hepatitis C Virus After Antiviral Treatment And Mixed Cryoglobulinemia 148
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 145
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. 143
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation 137
"Inapparent" hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease 136
Host genetic determinants in HCV-related mixed cryoglobulinemia 136
Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease 134
Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment 132
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 130
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. 129
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 129
Interferon and thymosin combination therapy in naive patients with chronic hepatitis C. Preliminary results 128
Chronic hepatitis C and B-cell non-Hodgkin's lymphoma 127
Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection 127
HCV-related mixed cryoglobulinemia and BAFF promoter polymorphism 125
COMBINED PRESENCE OF HCVRNA SEQUENCES AND T(14;18) (q32;q21) TRANSLOCATION IN PBMC FROM PATIENTS WITH CHRONIC HCV INFECTION. 125
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 124
Infection of peripheral mononuclear blood cells by hepatitis C virus 123
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. 122
T(14;18) translocation in chronic hepatitis C virus infection 121
Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients 121
Vertical transmission of HCV. 121
Can type C hepatitis infection be complicated by malignant lymphoma? 120
Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab 117
Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia 116
Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients 115
Analysis of HCV persistence in patients with sustained virological response 115
Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: The missing tool? 114
Combined presence of HCVRNA sequences and t(14;18) (q32;q21) translocation in PBMC from patients with chronic HCV infection 114
Host genetic determinants in HCV-related mixed cryoglobulinemia 112
Tryptophan/kynurenine pathway changes in HCV-infected patients: possible involvement in associated neuropsychiatry pathology 111
VALUE OF IL28B GENOTYPING IN PATIENTS WITH HCV-RELATED MIXED CRYOGLOBULINEMIA: RESULTS OF A LARGE, PROSPECTIVE STUDY 110
Hepatitis C virus (HCV) in cryoglobulinaemic leukocytoclastic vasculitis (LCV): could the presence of HCV in skin lesions be related to T CD8+ lymphocytes, HLA-DR and ICAM-1 expression? 110
HCV infection in mixed cryoglobulinemia and B-cell non-Hodgkin’s lymphoma. 109
HCV INFECTION OF PERIPHERAL AND LIVER MONONUCLEAR-CELLS - PATHOGENIC IMPLICATIONS 109
Lymphotropic virus infection of peripheral blood mononuclear cells in B-cell non-Hodgkin's lymphoma 107
Regression of T(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection. 107
A PROSPECTIVE-STUDY ON THE PREVALENCE OF ANTI HCV ANTIBODIES AND HCV-RNA IN SERA OF HEMODIALYSIS-PATIENTS 107
Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis 107
microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA 107
Hepatitis C virus lymphotropism and possible pathogenetic implications 106
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection 105
Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis 105
Hepatitis C virus infection in non-Hodgkin's B-cell lymphoma complicating mixed cryoglobulinaemia 104
Hepatitis C virus infection in patients with non-Hodgkin's lymphoma 104
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection. 104
Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases 103
Hepatitis C virus chronic infection as a common cause of mixed cryoglobulinaemia and autoimmune liver disease 103
Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications 102
Hepatitis C virus infection and B-cell lymphomas 102
Alterazioni del sistema pPAF-AH/PAF in pazienti con infezione cronica da HCV 101
Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis 98
Interstitial lung fibrosis in patients with hepatitis C virus infection 96
Lack of preferential localization of tumoral mass in B-cell non-Hodgkin's lymphoma associated with hepatitis C virus infection 94
Applicazione della metodica PCR (polymerase chain reaction) ed altre tecniche di biologia molecolare allo studio dell'infezione da virus C dell'epatite. 94
Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life 94
Mixed cryoglobulinemia as a possible preneoplastic disorder 92
Il polimorfismo dell'interleuchina 28B come predittore di risposta in pazienti con crioglobulinemia mista HCV-correlata 92
Could the presence of Mixed Cryoglobulinemia influence the outcome of standard peg-IFN plus ribavirin anti-HCV therapy? 92
Type C hepatitis and chronic lymphocytic leukaemia 91
Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection 91
Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia 89
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 89
Interferon-alpha in mixed cryoglobulinemia patients: a randomized crossover controlled trial 88
Genetic determinants in Hepatitis C Virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc-gamma receptors 88
Is T(14;18)(q32;q21) translocation a hallmark of HCV-related mixed cryoglobulinemia? 88
Comportamento dell'infezione da HCV in pazienti trapiantati per HCC complicante una cirrosi HCV-correlata 87
Behaviour of sustained responders to anti-HCV treatment: may HCV infection be eradicated? 87
Is t(14;18)(q32;q21) translocation a hallmark of HCV-related mixed cryoglobulinemia? 87
ETIOLOGICAL THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME: THE ROLE OF IL28B GENOTYPE AS PREDICTOR OF RESPONSE 87
Efficacia del trattamento antivirale nell’indurre la regressione di cloni B cellulari alberganti la traslocazione t(14;18) nell’infezione cronica da virus C dell’epatite (HCV). 86
Bcl-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment 85
Regression of T(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection. 84
HCV-related lymphatic and hepatic malignancies are associated with different microRNA expression patterns in PBMCs 84
Safety and effectiveness of boceprevir triple therapy in patients with mixed cryoglobulinemia 83
Tryptophan/Kynurenine pathway changes in HCV infected patients: possible involvment in associated neuropsychiathy pathology. 83
Tryptophan/kynurenine Patway Changes in HCV-infected Patients: Possible Involvement In Associated Neuropsychiatry Pathology 82
L'Impiego dell'INterferone Alfa Ricombinante nel Trattamento della Cirrosi Attiva anti-HCV positiva. 82
Different metabolic fingerprints between HCV and HBV patients: a possible interference of the two major hepatitis viruses in basal metabolism pathways. 81
E' possibile la trasmissione del virus C dell'epatite nei centri di dialisi mediante il passaggio attraverso la membrana emodialitica? Risultati di uno studio preliminare 81
Mixed cryoglobulinemia syndrome is a negative prognostic factor in the standard of care (Peg-IFN+ribavirin) anti-HCV therapy 81
ANALYSIS OF HCV INFECTION IN PATIENTS WITH B-CELL NON-HODGKINS-LYMPHOMA 80
Epatite da virus C e terapia interferonica 79
EFFECTS OF ALPHA-INTERFERON ON CRYOBULINEMIC HEPATITIS 79
Totale 11.819
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.156
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.156
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020792 0 0 0 0 0 0 0 245 200 161 163 23
2020/20211.342 122 60 91 160 52 184 47 111 116 219 95 85
2021/20221.052 13 109 44 58 46 38 32 70 47 25 204 366
2022/20232.576 247 345 134 187 246 531 356 132 268 16 74 40
2023/2024756 39 118 163 31 46 116 11 150 11 22 24 25
2024/20255.730 223 696 457 1.027 2.342 823 82 80 0 0 0 0
Totale 15.014